Answers are grounded in this paper and cite their sources.
Case report highlights immune checkpoint inhibitors' role in melanoma treatment, suggesting vitiligo may indicate better outcomes.
Recent advances in melanoma treatment have introduced several targeted therapies, including V-Raf murine sarcoma viral oncogene homolog B inhibitors, mitogen-activated protein kinase kinase inhibitors, mammalian target of rapamycin inhibitors, and immune checkpoint inhibitors (cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1 [PD-1] inhibitors), which have significantly transformed patient outcomes. These novel treatments have demonstrated marked improvements in both survival rates and quality of life for melanoma patients. While PD-1 blockade agents such as nivolumab and pembrolizumab represent a major therapeutic breakthrough, their use is frequently accompanied by immune-mediated adverse events, including cutaneous depigmentation, pulmonary inflammation, hepatic dysfunction, and thyroid abnormalities. This case report describes a 37-year-old female who developed vitiligo-like hypopigmented patches during nivolumab treatment for metastatic melanoma. The pathogenesis of this phenomenon likely involves cross-reactive activation of cytotoxic T lymphocytes that recognize shared antigens between malignant and normal melanocytes. Notably, the emergence of immunotherapy-induced vitiligo has been consistently linked with improved clinical outcomes, serving as a potential positive predictor for treatment response and enhanced survival in melanoma patients.
No takes yet. Share an insight, caveat, or question.
Malhan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: